Sun Pharmaceutical Industries has launched generic versions of Daiichi Sankyo medicines, used in the treatment of high blood pressure, in the US market. In a BSE filing, Sun Pharmaceutical Industries today said: its wholly owned subsidiary has launched in US, ... Business Line, 1 day ago
Sun Pharmaceutical launches 4 generics in US - India Infoline, 1 day ago
Sun Pharma launches blood pressure drugs in US - Business Standard, 1 day ago
More from: Business Standard, DNA...and 1 other sources
Daiichi Sankyo Company, Limited announced details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Europe 2017, a collaborative drug discovery initiative for universities and research institutes in Europe. TaNeDS ...PharmaBiz, 2 weeks ago DAIICHI SANKYO : Announces New Strategic Immuno-Oncology Research Collaboration with AgonOx 4 Traders, 2 weeks ago BRIEF-Daiichi Sankyo Co Ltd, Dana-Farber Cancer Institute today announce lung cancer research collaboration Reuters UK, 2 weeks ago Daiichi Sankyo to Present at ESMO 2016 Late-Breaking Clinical Data for Novel HER2-Targeting Antibody Drug Conjugate in T-DM1 Pre-Treated Breast Cancer Pharmacy Choice, 2 weeks ago
Daiichi Sankyo begins patient enrollment in phase 3 QuANTUM-First study of quizartinib in FLT3-ITD+ AML
Daiichi Sankyo Company, Limited announced that the first patient has been enrolled in the global phase 3 QuANTUM-First study evaluating the oral FLT3-ITD inhibitor quizartinib in patients with newly-diagnosed FLT3-ITD-positive (+) acute myeloid ...PharmaBiz, 2 weeks ago Daiichi Sankyo's late-stage study of leukemia candidate quizartinib underway Seeking Alpha, 2 weeks ago Daiichi Sankyo enrolls first patient in Phase 3 of QuANTUM-First trial for Quizartinib Drug Development Technology, 2 weeks ago BRIEF-Daiichi Sankyo begins enrollment for late-stage trial testing Quizartinib in leukemia patients Reuters UK, 2 weeks ago
Exelixis Announces Collaborator Daiichi Sankyo's Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor...
Exelixis Announces Collaborator Daiichi Sankyo's Initiation of Phase 3 Clinical Development for CS-3150, a Selective Mineralocorticoid Receptor Antagonist By a News Reporter-Staff News Editor at Heart Disease Weekly Exelixis, Inc. (NASDAQ:EXEL) ...Pharmacy Choice, 3 weeks ago Exelixis' collaborator Daiichi Sankyo begins phase 3 trial to evaluate CS-3150 to treat hypertension PharmaBiz, 1 month ago Daiichi Sankyo launches Phase 3 clinical trial of CS-3150 in Japanese patients with high blood pressure triggering $15M milestone to Exelisis Seeking Alpha, 1 month ago DAIICHI SANKYO : Initiates Phase 3 study of CS-3150, a Novel Mineralocorticoid Receptor Antagonist for Treatment of Essential Hypertension 4 Traders, 1 month ago
Daiichi Sankyo Company, Limited announced that it has commenced a company-initiated, large-scale registry, called ANAFIE (All Nippon AF In Elderly) Registry in Japan to study nonvalvular atrial fibrillation (hereafter, NVAF) in elderly patients aged ...PharmaBiz, 3 weeks ago DAIICHI SANKYO : Announces Large-Scale Registry of Nonvalvular Atrial Fibrillation in the Elderly 4 Traders, 3 weeks ago Daiichi Sankyo Announces Large-Scale Registry of Nonvalvular Atrial Fibrillation in the Elderly FirstWord Pharma, 3 weeks ago
Zymeworks, Daiichi Sankyo ink cross-licensing & collaboration to develop cancer immuno-oncology drugs
Zymeworks Inc., a clinical-stage biopharmaceutical company, and Daiichi Sankyo Company, Limited have entered into a cross-licensing and collaboration agreement to develop proprietary cancer immuno-oncology products. Under the terms of the ...PharmaBiz, 4 weeks ago ArticleZymeworks and Daiichi Sankyo ink immuno-oncology cross-licensing deal29-09-2016 Pharma Letter, 4 weeks ago Zymeworks and Daiichi Sankyo partner on bi-Specific antibody and immuno-oncology cross-licensing deal BiotechnologyFocus.ca, 4 weeks ago Zymeworks and Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement and Bi-Specific Antibody Collaboration Minyanville, 4 weeks ago
Daiichi Sankyo Company, Limited announced that it has applied for additional indication of denosumab (product name: Pralia subcutaneous injection 60mg syringe) for rheumatoid arthritis-related treatment. Denosumab is the first fully human ...PharmaBiz, 1 month ago Daiichi Sankyo Announces Application in Japan for Additional Indication for Anti-RANKL Antibody, Denosumab FirstWord Pharma, 1 month ago
By a News Reporter-Staff News Editor at Drug Week Daiichi Sankyo, Inc. announced the appointment of Marielle Cohard-Radice, MD as Executive Vice President, Global Head of Development, effective September 2, 2016 (see also Pharmaceutical Companies). ...Pharmacy Choice, 1 month ago Daiichi Sankyo appoints Marielle Cohard-Radice Global Head of Development Center Watch, 1 month ago Daiichi Sankyo promotes Marielle Cohard-Radice to new global head of development Pharma Letter, 1 month ago New Global Head of Development for Daiichi Sankyo PharmExec.com, 1 month ago
More from: Nasdaq, Reuters UK...and 11 other sources
DAIICHI SANKYO : Recent Studies from Daiichi Sankyo Add New Data to Anions (Scintillation Proximity Assay to Detect the Changes in Cellular Dihydrosphingosine...
Recent Studies from Daiichi Sankyo Add New Data to Anions (Scintillation Proximity Assay to Detect the Changes in Cellular Dihydrosphingosine 1-Phosphate Levels) By a News Reporter-Staff News Editor at Health & Medicine Week -- Investigators ...4 Traders, 2 weeks ago DAIICHI SANKYO : Studies from Daiichi Sankyo Yield New Data on Glycoside Hydrolases (Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure... 4 Traders, 3 weeks ago DAIICHI SANKYO : Reports from Daiichi Sankyo Add New Data to Findings in Thrombosis (Prevention of arterial thrombosis by edoxaban, an oral factor Xa inhibitor in... 4 Traders, 1 month ago DAIICHI SANKYO : New Findings on Carboxylic Ester Hydrolases from Daiichi Sankyo Summarized (Identification of a novel boronic acid as a potent, selective, and orally... 4 Traders, 1 month ago
Daiichi Sankyo Announces New Data to be Presented at the ISPOR EU Congress 2016 Analysing the Safety, Efficacy and Cost-effectiveness of LIXIANA® (edoxaban) - Three abstracts highlight the economic burden of Venous Thromboembolism (VTE) in Europe ...Ariva.de, 2 weeks ago Venous thromboembolism (VTE): New analysis shows maintained efficacy and safety of LIXIANA Medical News Today, 3 weeks ago New Analysis Shows Maintained Efficacy and Safety of LIXIANA®▼ (edoxaban) in Patients with Acute VTE Requiring a Reduced Dose Based on Clinical Criteria PharmaVOICE, 3 weeks ago
on your WebpageAdd Widget >Get your members hooked!